Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Biotech M&A hits $106B in 2026, on track for strongest year since 2019 amid patent cliffs and China interest.

Market News
04 Jun 2026
CNBC
View Source
Bullish
pluang ai news

Biotech and pharma mergers and acquisitions (M&A) reached $106 billion across 201 deals in early 2026, driven by urgent needs to replace revenue from expiring drug patents and renewed investor interest. Despite rising interest rates and inflation, dealmaking momentum remains strong, focusing on strategic bolt-on acquisitions in the $1-5 billion range rather than mega-mergers. Companies are increasingly scouting innovative assets from China to boost pipelines, leveraging cross-border deals to access global markets. If this pace continues, 2026 could surpass $250 billion in deal value, marking the sector's strongest year since 2019.

More News (GSK)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App